Who are Cephadol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Incruse Ellipta, Pentam, Antrenyl, Methylrosaniline Chloride, Salagen, Pro-Banthine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/diphenidol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Cephadol — Competitive Intelligence Brief

Cephadol (DIPHENIDOL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiemetic. Area: Neuroscience.

marketed Antiemetic Muscarinic acetylcholine receptor M4 Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Cephadol (DIPHENIDOL).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cephadol TARGET	DIPHENIDOL		marketed	Antiemetic	Muscarinic acetylcholine receptor M4	1967-01-01
Incruse Ellipta	UMECLIDINIUM	Glaxo Grp England	marketed	Anticholinergic	Muscarinic acetylcholine receptor M4	2013-01-01
Pentam	PENTAMIDINE	Fresenius Kabi	marketed	Antiprotozoal	Muscarinic acetylcholine receptor M4	1984-01-01
Antrenyl	OXYPHENONIUM	Novartis	marketed	oxyphenonium	Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M3, Muscarinic acetylcholine receptor M4	1982-01-01
Methylrosaniline Chloride	GENTIAN VIOLET		marketed		Muscarinic acetylcholine receptor M4	1982-01-01
Salagen	PILOCARPINE		marketed	Cholinergic Receptor Agonist	Muscarinic acetylcholine receptor M4	1974-01-01
Pro-Banthine	PROPANTHELINE		marketed	Anticholinergic	Muscarinic acetylcholine receptor M4	1953-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiemetic class)

· 1 drug in this class
Citron Pharma Llc · 1 drug in this class
Newark Beth Israel Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cephadol — Competitive Intelligence Brief. https://druglandscape.com/ci/diphenidol. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab